CRP and colorectal carcinoma: The impact in patients with metastatic MSS-CRC might entail the opportunity of ICB therapy based on CRP as a dynamic measure [35] during oxaliplatin-based chemotherapy, starting when this pragmatic inflammation marker has become sufficiently low.